BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 1299978)

  • 1. [Pulmonary toxicity of nilutamide (Anandron). Cooperative evaluation of French Regional Pharmacovigilance Centers].
    Jonville AP; Diot E; Dutertre JP; Autret E
    Therapie; 1992; 47(5):393-7. PubMed ID: 1299978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Fatal fulminant hepatitis induced by nilutamide (Anandron)].
    Pescatore P; Hammel P; Durand F; Bertheau P; Bernuau J; Huc D; Gerbal JL; Degott C; Benhamou JP
    Gastroenterol Clin Biol; 1993; 17(6-7):499-501. PubMed ID: 8243938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study.
    Boccardo F; Decensi AU; Guarneri D; Martorana G; Fioretto L; Mini E; Macaluso MP; Giuliani L; Santi L; Periti P
    Cancer Detect Prev; 1991; 15(6):501-3. PubMed ID: 1782640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report.
    Gomez JL; Dupont A; Cusan L; Tremblay M; Tremblay M; Labrie F
    Am J Med; 1992 May; 92(5):563-6. PubMed ID: 1580304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
    Kassouf W; Tanguay S; Aprikian AG
    J Urol; 2003 May; 169(5):1742-4. PubMed ID: 12686822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiandrogen withdrawal syndrome with nilutamide.
    Gomella LG; Ismail M; Nathan FE
    J Urol; 1997 Apr; 157(4):1366. PubMed ID: 9120950
    [No Abstract]   [Full Text] [Related]  

  • 7. [Fatal fulminating hepatitis caused by nilutamide. A new case].
    Marty F; Godart D; Doermann F; Mérillon H
    Gastroenterol Clin Biol; 1996; 20(8-9):710-1. PubMed ID: 8977826
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.
    Nakabayashi M; Regan MM; Lifsey D; Kantoff PW; Taplin ME; Sartor O; Oh WK
    BJU Int; 2005 Oct; 96(6):783-6. PubMed ID: 16153200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Amiodarone-induced pleuropneumopathies: experience 1983-1993 in a drug vigilance Regional Center].
    Graille V; Lapeyre-Mestre M; Montastruc JL
    Therapie; 1994; 49(5):421-4. PubMed ID: 7855756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of nilutamide by NO synthases: implications for the adverse effects of this nitroaromatic antiandrogen drug.
    Ask K; Dijols S; Giroud C; Casse L; Frapart YM; Sari MA; Kim KS; Stuehr DJ; Mansuy D; Camus P; Boucher JL
    Chem Res Toxicol; 2003 Dec; 16(12):1547-54. PubMed ID: 14680368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical study of RU 23908 (nilutamide) in prostatic cancer].
    Akaza H; Aso Y; Niijima T; Fuse H; Izaka S; Akimoto S; Shimazaki J; Imai K; Yamanaka H; Kihara K
    Hinyokika Kiyo; 1991 Apr; 37(4):407-20. PubMed ID: 1892002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of free radicals during the reductive metabolism of nilutamide by lung microsomes: possible role in the development of lung lesions in patients treated with this anti-androgen.
    Berger V; Berson A; Wolf C; Chachaty C; Fau D; Fromenty B; Pessayre D
    Biochem Pharmacol; 1992 Feb; 43(3):654-7. PubMed ID: 1311586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary complications of hormone treatment in prostate carcinoma.
    Seigneur J; Trechot PF; Hubert J; Lamy P
    Chest; 1988 May; 93(5):1106. PubMed ID: 3129240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nilutamide pneumonitis: a report on eight patients.
    Pfitzenmeyer P; Foucher P; Piard F; Coudert B; Braud ML; Gabez P; Lacroix S; Mabille JP; Camus P
    Thorax; 1992 Aug; 47(8):622-7. PubMed ID: 1412120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer: a multicenter comparative study of two doses of the drug and of a placebo.
    Brisset JM; Boccon-Gibod L; Botto H; Camey M; Cariou G; Duclos JM; Duval F; Gontiès D; Jorest R; Lamy L
    Prog Clin Biol Res; 1987; 243A():411-22. PubMed ID: 3309973
    [No Abstract]   [Full Text] [Related]  

  • 16. [Fever caused by fipexide. Evaluation of the national pharmacovigilance survey].
    Guy C; Blay N; Rousset H; Fardeau V; Ollagnier M
    Therapie; 1990; 45(5):429-31. PubMed ID: 2260037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma.
    Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM; Tewari HD
    Cancer; 1990 Sep; 66(5 Suppl):1074-9. PubMed ID: 2203517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Acute depressive syndrome possibly due to nilutamide (Anandron) treatment].
    Maroy B; Pitrou P
    Therapie; 1997; 52(1):79-81. PubMed ID: 9183930
    [No Abstract]   [Full Text] [Related]  

  • 19. ["Eosinophilia-myalgia" syndrome due to L-tryptophan containing products. Cooperative evaluation of French Regional Centers of Pharmacovigilance. Analysis of 24 cases].
    Castot A; Bidault I; Bournerias I; Carlier P; Efthymiou ML
    Therapie; 1991; 46(5):355-65. PubMed ID: 1754978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comment: clinical experiences of visual disturbances with nilutamide.
    Dijkman GA; Klotz LH; Diokno AC; Zippe CD
    Ann Pharmacother; 1997 Dec; 31(12):1550-2. PubMed ID: 9416403
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.